[177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Swayamjeet Satapathy; Ranjit K. Sahoo; Chandrasekhar Bal

doi:10.2967/jnumed.123.265414

Research ArticleClinical Investigation

[¹⁷⁷Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Swayamjeet Satapathy, Ranjit K. Sahoo and Chandrasekhar Bal

Journal of Nuclear Medicine May 2023, 265414; DOI: https://doi.org/10.2967/jnumed.123.265414

Swayamjeet Satapathy

1Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ranjit K. Sahoo

2Department of Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chandrasekhar Bal

1Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Article Information

265414

DOI

https://doi.org/10.2967/jnumed.123.265414

PubMed

37169534

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication January 5, 2023
Revision received March 10, 2023
Published online May 11, 2023.

Article Versions

You are currently viewing a previous version of this article (May 11, 2023 - 08:51).
View the most recent version of this article

Author Information

Swayamjeet Satapathy¹,
Ranjit K. Sahoo² and
Chandrasekhar Bal¹

¹Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India; and
²Department of Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

For correspondence or reprints, contact Chandrasekhar Bal (csbal{at}hotmail.com).

View Full Text

Statistics from Altmetric.com

Cited By...

16 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

PSMA Radioligand Therapy in Prostate Cancer

Ludmila Santiago Almeida, Elba Cristina Sá de Camargo Etchebehere, Irene García Megías, Adriana K. Calapaquí Terán, Boris Hadaschik, Patrick M. Colletti, Ken Herrmann, Francesco Giammarile, Roberto C. Delgado Bolton

Clinical Nuclear Medicine 2024 49 1
[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial

Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, Shrawan Kumar Singh

Journal of Nuclear Medicine 2023 64 11
Promising Therapeutic Activity of 177Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer

Swayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Chandrasekhar Bal

Clinical Nuclear Medicine 2024 49 2
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad

Current Oncology 2024 31 3
[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study

Swayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Chandrasekhar Bal

European Journal of Nuclear Medicine and Molecular Imaging 2024 51 8
PSMA-based therapeutics for prostate cancer

Panagiotis Velissarios Stamatakos, Charalampos Fragkoulis, Aggeliki Leventi, Konstantinos Gklinos, Nikolaos Kontolatis, Athanasios Papatsoris, Athanasios Dellis

Expert Opinion on Pharmacotherapy 2024 25 10
Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Ludmila Santiago Almeida, Irene García Megías, Elba Cristina Sá Camargo Etchebehere, Adriana K. Calapaquí Terán, Ken Herrmann, Francesco Giammarile, Giorgio Treglia, Roberto C. Delgado Bolton

European Journal of Nuclear Medicine and Molecular Imaging 2025 52 3
Radiopharmaceuticals for Cancer Diagnosis and Therapy

Neil K. Taunk, Freddy E. Escorcia, Jason S. Lewis, Lisa Bodei

The Cancer Journal 2024 30 3
A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer

Richard F. Liu, Cristiano Ferrario, Parvaneh Fallah, April A.N. Rose, Soumaya Labidi, Aline Mamo, Stephan M. Probst

Nuclear Medicine Communications 2024 45 8
Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer—A case report

Carsten S. Kramer, Jingjing Zhang, Richard P. Baum

Frontiers in Medicine 2024 11

Article usage

Article usage: May 2023 to March 2025

	Abstract	Full	Pdf
May 2023	1685	88	64
Jun 2023	415	25	19
Jul 2023	286	37	29
Aug 2023	1055	66	63
Sep 2023	575	37	32
Oct 2023	339	55	24
Nov 2023	101	182	46
Dec 2023	42	87	55
Jan 2024	77	174	57
Feb 2024	62	263	50
Mar 2024	24	176	51
Apr 2024	35	164	66
May 2024	41	147	48
Jun 2024	27	185	46
Jul 2024	32	281	80
Aug 2024	22	247	65
Sep 2024	27	86	66
Oct 2024	18	81	35
Nov 2024	19	83	39
Dec 2024	11	88	27
Jan 2025	22	109	44
Feb 2025	20	217	58
Mar 2025	33	158	177

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 4

April 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following [177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

[¹⁷⁷Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Swayamjeet Satapathy, Ranjit K. Sahoo, Chandrasekhar Bal

Journal of Nuclear Medicine May 2023, 265414; DOI: 10.2967/jnumed.123.265414

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

[¹⁷⁷Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Swayamjeet Satapathy, Ranjit K. Sahoo, Chandrasekhar Bal

Journal of Nuclear Medicine May 2023, 265414; DOI: 10.2967/jnumed.123.265414

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial

Google Scholar

Keywords

mCRPC
[177Lu]Lu-PSMA
radioligand therapy
chemotherapy
metaanalysis

Main menu

User menu

Search

[¹⁷⁷Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis

Article Information

Article Versions

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: May 2023 to March 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords